RT Journal Article
SR Electronic
T1 Efficacy and Safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three doses combination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.31.21265703
DO 10.1101/2021.10.31.21265703
A1 Toledo-Romani, M. Eugenia
A1 Garcia-Carmenate, M.
A1 Silva, C. Valenzuela
A1 Baldoquin-Rodriguez, W.
A1 Pérez, M. Martínez
A1 Rodríguez Gonzalez, M. C.
A1 Moreno, B. Paredes
A1 Hernández, I. C. Mendoza
A1 Romero, R. González-Mujica
A1 Tabio, O. Samón
A1 Villares, P. M. Velazco
A1 Castillo, J. P. Bacallao
A1 Martín, E. Licea
A1 Ortega, M. Rodríguez
A1 Marrero, N. L. Herrera
A1 Gonzalez, E. Caballero
A1 Egües Torres, L. I.
A1 González, R. Duarte
A1 Blanco, S. García
A1 Cabrera, S. Pérez
A1 Ferreira, S. Huete
A1 Cisnero, K. Idalmis
A1 Galindo, O. Fonte
A1 Pérez, D. Meliá
A1 Remedios, I. Rojas
A1 Castillo, S. Fernandez
A1 Ruiz, Y. Climent
A1 Valdes-Balbin, Y.
A1 Garcia-Rivera, D.
A1 Bencomo, V. Verez
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/11/01/2021.10.31.21265703.abstract
AB Background SOBERANA 02 is a COVID19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoid). Phase 1 and 2 clinical trials demonstrated its high immunogenicity, promoting neutralizing IgG together with specific T-cell response. A third dose of SOBERANA Plus (SARS-CoV-2 RBD-dimer) further increased the specific anti-RBD neutralizing antibodies.Methods In a randomized, double-blinded, placebo-controlled, phase 3 trial we randomly assigned 44 031 participants, aged 19-80 years to three groups in a 1:1:1 ratio to receive 28 days apart either a) two doses of 25 μg SOBERANA 02, or b) two doses of 25 μg SOBERANA 02 followed by a third dose of 50 μg SOBERANA Plus, or c) two doses of placebo. Reported study endpoints are vaccine efficacy (VE) evaluated through laboratory-confirmed symptomatic COVID-19 cases and safety. During the trial, the SARS CoV-2 isolates in Havana were predominantly (β, 74.0 %) and shift gradually to δ (100%).Results Two doses of SOBERANA 02 protects against symptomatic COVID-19: 43 cases in the two-dose group (14 371) vs. 155 in the placebo group (14 403), VE 71.0%, adjusted (CI 95%58.9-79.1). The heterologous three dose combination with SOBERANA Plus protected against symptomatic COVID-19: 15 cases in the vaccine groups (13 833) vs. 155 in the placebo group (14 303), VE 92.4%, adjusted (CI 95% 86.9-95.6%). For two-dose schedule VE against severe COVID-19 was 63.0% and for death 59.0%; for heterologous three-dose schedule, 100% in both cases.Conclusions This is the first phase 3 study of a three-dose, heterologous vaccine combination against SARS-CoV-2. Two doses of the conjugate vaccine SOBERANA 02 was safe and attained efficacy of 71.0% in adult’s population 19-80 y/o; incorporating SOBERANA Plus after two doses of SOBERANA 02, increased efficacy from 71.0 % to 92.4% (Clinical Trials IFV/COR/09 number, RPCEC00000354.)Competing Interest Statement(M. M. P, M. C. R. G., B. P. M., R. G.M. R., E. L. M., E.C.G., S. F., Y. C., Y. V.B., D. G.R., V. V. B.) are from Finlay Vaccine Institute the sponsor of the trialClinical TrialRPCEC00000354 International Clinical Trials Registry Platform. IdentifierFunding StatementSupported by Finlay Vaccine Institute, Biocubafarma and by Fondo Nacional de Ciencia y Tecnica (FONCI-CITMA-Cuba, contract 2020-20).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Central Research Ethics Committee from the Cuban Ministry of Health was ad hoc appointed for this trial. They approved the protocol (Clinical Trials IFV/COR/09 number, RPCEC00000354) and the consent forms.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://rpcec.sld.cu/en/trials/RPCEC00000354-En